The 2nd International Babylon Conference on Clinical and Experimental Pharmacological Research: focusing on drug development and repurposing, drug safety, and public health
DOI:
https://doi.org/10.60988/p.v37i2S.129Keywords:
Iraq; pharmacological research; drug development; drug safety; public healthAbstract
The proceedings of the 2nd International Babylon Conference on Clinical and Experimental Pharmacological Research (taking place at the College of Pharmacy of the University of Babylon, in Hillah, Iraq; April 19-20, 2025) are hereby hosted by Pharmakeftiki; a journal founded by the Hellenic Society of Medicinal Chemistry (HSMC) in 1988 and currently published independently with the support of both the HSMC and the Hellenic Pharmaceutical Society. This year’s conference proceedings are more extensive in terms of both the number of papers included in them and the thematic representation of the field. In that respect, the conference’s scientific programme exhibits an encouraging enrichment that also signifies the importance of this event for the Iraqi pharmacological community. The proceedings cover the main messages of the keynote speakers’ talks, present the findings of a large number of clinical, epidemiological, and experimental research studies, and also host interesting (mini-)reviews on important pharmacological topics that, in most cases, are penned by postgraduate students and their supervisors, as part of their degree prerequisites. The conference’s committees have successfully established an international forum for the discussion of critical developments in pharmacological research, with this year’s conference focusing on drug development and repurposing, drug safety, and public health.
References
Liapi C., Zarros A. The 1st International Babylon Conference on Clinical and Experimental Pharmacological Research: mapping the Iraqi pharmacological research activity and priorities. Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 38(s2), 1–2, 2024. DOI: 10.61873/VBNU2182
Al-Jumaili A.A., Younus M.M., Kannan Y.J.A., Nooruldeen Z.E., Al-Nuseirat A. Pharmaceutical regulations in Iraq: from medicine approval to postmarketing. East. Mediterr. Health J. 27(10), 1007–1015, 2021. DOI: 10.26719/emhj.21.025
Fadheel Q.J., Mohammed R.A. Study of the spread of medicinal herbs use among patients suffering from chronic diseases in Iraq. Pol. Merkur. Lekarski 52(1), 73–78, 2024. DOI: 10.36740/Merkur202401112
Al-Jumaili A.A., Younus M.M., Saleh M.Z. The epidemic of substandard and falsified medications in Iraq: evaluating the effectiveness of national pharmacovigilance alerts to community pharmacies. Pharmaceut. Med. 35(3), 169–186, 2021. DOI: 10.1007/s40290-021-00386-9
Kasim H.F., Salih A.İ., Al Hamdany H. Knowledge and attitude of Iraqi pharmacists regarding the adverse effects of NSAIDs based on years of experience. Turk. J. Pharm. Sci. 22(1), 26–37, 2025. DOI: 10.4274/tjps.galenos.2024.92185
Lawi D.J., Abdulwhaab W.S., Abojassim A.A. Potential health risks of Zn, Fe, and Pb in medical skin creams and cosmetic products derived from plants in Iraq. Biol. Trace Elem. Res. 201(8), 4167–4176, 2023. DOI: 10.1007/s12011-022-03493-z
Al-Jumaili A.A., Ahmed K.K. A review of antibiotic misuse and bacterial resistance in Iraq. East. Mediterr. Health J. 30(10), 663–670, 2024. DOI: 10.26719/2024.30.10.663
Lami F., Rashak H.A., Khaleel H.A., Mahdi S.G., Adnan F., Khader Y.S., et al. Iraq experience in handling the COVID-19 pandemic: implications of public health challenges and lessons learned for future epidemic preparedness planning. J. Public Health (Oxf.) 43(s3), iii19–iii28, 2021. DOI: 10.1093/pubmed/fdab369
Merzah M. Trends in incidence, prevalence, and mortality of non-communicable diseases in Iraq (2003–2021). BMC Public Health. 25(1), 374, 2025. DOI: 10.1186/s12889-024-21080-w
